HOME >> BIOLOGY >> NEWS
Aggressive subtype of breast cancer displays 'misbehavior' of X chromosomes

Basal-like breast cancers (BLC) are highly aggressive tumors with a relatively poor prognosis that account for approximately 15% of sporadic human breast cancer. Sporadic BLC share certain characteristics with most of the breast cancers from patients carrying a germline mutation in the BRCA1 breast cancer suppressor gene. Among their similarities, sporadic BLC and BRCA1 cancers do not express the estrogen receptor and do not overproduce HER2 protein. Thus, therapeutics targeting estrogen receptor or targeting HER2 currently used in treating some other types of breast cancers are unlikely to be useful for treating these breast cancers. However, sporadic BLC contain normal BRCA1 genes. A new study published in the February issue of Cancer Cell provides evidence that X chromosome abnormalities contribute to the pathogenesis of both the sporadic BRCA1 normal BLC and the inherited BRCA1 mutant breast cancer.

Defects in the BRCA1 gene have been linked to an abnormality in a mechanism that contributes to the stability of sex chromosomes in women. In mammals, male cells contain an X and a Y chromosome, while female cells contain two X chromosomes. Normally, a process called X inactivation occurs in early female embryos; it leads to silencing of one of the two X chromosomes in derivative embryonic and adult somatic cells. The authors had previously shown that loss of the inactive X chromosome (Xi) occurs in BRCA1 mutation-carrying breast cancers. Given the similarities between BRCA1-associated cancer and sporadic BLC, Drs. Andrea Richardson, Zhigang Wang, Dirk Iglehart, David M. Livingston, and Shridar Ganesan, and colleagues from the Dana-Farber Cancer Institute and Brigham and Women's Hospital, examined whether sporadic BLC display abnormalities in the management of the Xi chromosome.

The researchers found that, like BRCA1-associated cancers, most sporadic BLC have consistently lost the Xi and displayed a higher than normal number of apparently active X ch
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
13-Feb-2006


Page: 1 2

Related biology news :

1. Aggressive therapy best for certain AML patients
2. Aggressive aquatic species invading Great Lakes
3. deCODE discovers cause of major subtype of glaucoma
4. Genes activity points to more lethal subtype of AML
5. Three new lung tumor subtypes identified in DNA profiling study
6. HPV subtype associated with squamous cell skin cancers
7. Newly created cancer stem cells could aid breast cancer research
8. New study suggests Concord grape juice may provide protection against breast cancer
9. U-M researchers identify gene involved in breast cancer
10. Additional mammogram readers improve breast cancer detection
11. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
(Date:6/25/2020)... ... 24, 2020 , ... eClinical Solutions LLC , a ... accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on ... severe COVID-19. This is the first study of an XPO1 inhibitor in patients ...
(Date:6/23/2020)... ... June 23, 2020 , ... First ... Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable energy equipment, ... in the fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... entered into a strategic partnership whereby Catalent will provide support for the development, ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech ... Regulatory Solutions, in a one hour live webinar on Thursday, August 13, ... China for drugs and medical devices. Specifically, for medical devices, the NMPA has departments ...
(Date:7/18/2020)... , ... July 17, 2020 , ... ... consulting firm for the life sciences and food industries, is pleased to announce ... of Clinical Research – Business Development. , Charles is an accomplished and results-driven ...
Breaking Biology Technology:
Cached News: